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A B S T R A C T
Objectives: The prevalence of active, chronic, and former hepatitis E virus (HEV) infections was
investigated in a cohort of immunocompromised patients. The association with transfusion transmitted
HEV was evaluated, and the HEV seroprevalence was compared with that in healthy blood donors.
Study design and methods: Serum samples from 4023 immunocompromised patients at Rigshospitalet,
Denmark were retrospectively tested for HEV RNA and anti-HEV IgG. HEV RNA-positive patients were
followed up by HEV testing, clinical symptoms, and transfusion history. Factors associated with anti-HEV
were explored by multivariable logistic regression analysis. Samples from 1226 blood donors were
retrospectively tested for anti-HEV IgG.
Results: HEV RNA was detected in six patients (0.15%) with no indications of chronic HEV infection. HEV
RNA prevalence rates among recipients of allogeneic haematopoietic stem cell transplantation (allo-
HSCT) and solid organ transplantation (SOT) were 0.58% and 0.21%, respectively. Transfusion transmitted
infections were refuted, and transfusion history was not associated with anti-HEV positivity. The
difference in HEV seroprevalence between patients (22.0%) and blood donors (10.9%) decreased when
adjusting for age and sex (odds ratio 1.20, 95% confidence interval 0.97–1.48).
Conclusions: HEV viremia among allo-HSCT and SOT recipients suggests that clinicians should be aware of
this diagnosis. The lack of association of blood transfusion with anti-HEV positivity supports food-borne
transmission as the main transmission route of HEV common to both patients and blood donors.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The zoonotic hepatitis E virus genotype 3 (HEV-3) causes human
infections in Europe, with pigs serving as the predominant
reservoirs. In Denmark, HEV-3 is widespread in pig herds and in
pigs at the time of slaughter (Breum et al., 2010; Kroget al., 2019). The
transmission of HEV-3 is mainly associated with the consumption of
contaminated foodstuff, but transmission by blood transfusion andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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with HEV-3 usually leads to silent seroconversion. However,
immunocompromised patients have been shown to develop chronic
infections with the risk of cirrhosis (Kamar et al., 2008; Abravanel
et al., 2014). In Denmark, the HEV RNA prevalence was 0.04% among
healthy blood donors in 2015 (Harritshoj et al., 2016). However, the
HEV epidemiology in immunocompromised patients is unknown.
Immunocompromised patients may have a higher HEV RNA
prevalence and HEV seroprevalence due to the possibility of chronic
infection from environmental/food exposure and any exposure to
transfusion-transmitted HEV (Tedder et al., 2017).
The primary aim of this cross-sectional study was to determine
the HEV RNA prevalence in a wide spectrum of immunocompro-
mised patients in Denmark and to describe the clinical course of
HEV infection in this cohort. Secondary aims included the
assessment of the association of transfusion history with active
and former HEV infections among immunocompromised patients.
Furthermore, we wanted to compare the prevalence of anti-HEV
IgG between immunocompromised patients and healthy blood
donors in Denmark, a country with a large pig industry.
Materials and methods
Study population, blood samples, and laboratory data—patients
PERSIMUNE is a centre of excellence in Rigshospitalet,
Denmark, which serves a broad range of patient groups with
impaired immune function, who are followed in the PERSIMUNE
cohort (inclusion criteria are mainly solid organ transplantation
(SOT), allogeneic haematopoietic stem cell transplantation
(allo-HSCT), malignant or solid organ or haematological disease,
rheumatological immunomodulation  treatment, HIV infection).
Enrolment in PERSIMUNE is independent of the time of
inclusion diagnosis. The cohort is affiliated with the PERSIMUNE
BioBank. Patients providing informed consent are enrolled in
the BioBank, with blood samples drawn at enrolment and at
follow-up time points. Frozen plasma samples obtained at
enrolment from patients 18 years old enrolled in the
PERSIMUNE BioBank between April 1, 2015 and May 15, 2017
were included in the study. Follow-up samples from patients
with HEV RNA viraemia were samples from the PERSIMUNE
BioBank or specific sampling after informed consent, according
to ethical scientific approval H-16040755. Demographic data,
affiliated department, routine laboratory data, status on
treatment with transplantation (TX) with either SOT or allo-
HSCT, and HIV diagnosis were available from the patient
treatment databases. Patient transfusion histories were avail-
able from the laboratory information system in the Capital
Region Blood Service. Transfusion histories from blood banks in
other regions of Denmark were not available.
Study population, blood samples, and demographic data—blood
donors
Frozen HEV RNA-negative plasma samples chosen randomly
(5%) from a blood donor study of HEV RNA prevalence in Denmark
performed from January 12 to February 13, 2015 were included in
the study (Harritshoj et al., 2016). Sex and age at donation were
available demographic data.
HEV RNA detection and genotyping
All patient samples were retrospectively tested for HEV RNA
using a CE-marked commercial qualitative nucleic acid amplifica-
tion test (NAT) on automated analysers (Procleix HEV Assay on
Procleix Panther Systems; Grifols Diagnostic Division, Emeryville,CA, USA). The assay detects HEV of genotypes 1–4 and uses
transcription-mediated amplification to amplify highly conserved
regions of HEV RNA targeted by captured oligonucleotides (Sauleda
et al., 2015). Initially reactive HEV RNA samples were confirmed by
Sanquin Blood Supply in the Netherlands for HEV RNA quantifica-
tion and genotyping using methods described previously (Ijaz
et al., 2014; Hogema et al., 2016). Due to limited sample material, a
1.25 dilution of samples was necessary to extract RNA from 0.4 ml
of sample using the QIAamp MinElute Virus Spin Kit (Qiagen,
Hilden, Germany). The PCR assay amplified a 74-bp fragment of
open reading frame region 3 (ORF-3) of HEV with a 95% lower limit
of detection (LLD) of 10.3 IU/ml in undiluted samples. HEV
genotyping was performed by amplification and sequencing of
242-bp and 302-bp fragments of ORF-1 and ORF-2 and a 1390-bp
fragment of ORF-2, as described elsewhere (Ijaz et al., 2014;
Hogema et al., 2016). GenBank accession numbers are MN602942–
MN602947.
Anti-HEV serology
HEV antibodies were detected using the Wantai Hepatitis E IgG
and IgM ELISA (Nordic BioSite, Copenhagen, Denmark), performed
according to the manufacturer’s instructions, using a signal/cut-off
(S/CO) ratio of 1.1 to define a positive result. Samples with a
borderline S/CO ratio (0.9–1.1) were re-tested. All patient and
donor samples were tested for anti-HEV IgG. Anti-HEV IgM testing
was conducted for anti-HEV IgG or HEV RNA reactive samples.
Follow-up of HEV RNA-positive patients
A patient was considered HEV RNA reactive by enrolment in
the PERSIMUNE cohort, if the patient’s sample was confirmed
HEV RNA reactive by confirmatory PCR test or if anti-HEV
seroconversion was detected in a follow-up sample. Follow-up
samples were tested for HEV RNA and HEV IgG and IgM
antibodies. Plasma (p) liver enzyme alanine aminotransferase
(p-ALT), p-bilirubin, p-creatinine, leukocyte count, and leukocyte
subpopulations were reviewed from the treatment data obtained
from enrolment (and nearest data within 1 year before enrol-
ment) until the date of the latest follow-up sample. The
persistence of HEV was defined by HEV viraemia for 6 months
or more. Patient notes were investigated for the clinical
symptoms of an HEV infection. Look-back procedures included
HEV RNA and IgG testing of archived samples from blood
transfusions received by HEV RNA-positive patients up to 6
months before enrolment in PERSIMUNE.
Phylogenetic analyses
Sequence alignment and construction of a neighbour-joining
phylogenetic tree using the Tamura–Nei algorithm were per-
formed using Mega software (version 10) and Figtree version 1.4.
Genotype and tentative subtypes were assigned by comparison
with sequences from the HEV reference set proposed by the
International Committee on Taxonomy of Viruses (ICTV) Herpes-
viridae study group (Smith et al., 2016).
Statistical analysis
Nominal data were presented as percentages with 95%
confidence intervals (CI), and continuous data were presented as
medians with the interquartile ranges (IQR). Differences in
frequency distributions were tested using the Chi-square test.
Multivariable logistic regression was used to examine factors
associated with positive anti-HEV IgG results and included age
(linear), sex, previous blood transfusions (linear), allogeneic HSCT
190 L.H. Harritshøj et al. / International Journal of Infectious Diseases 91 (2020) 188–195or SOT, and HIV status; odds ratios (ORs) with 95% CI were
calculated. For the comparison of HEV seropositivity between
patients and donors, multivariable logistic regression analysis was
used to adjust for age and sex. The statistical analysis was
performed in R (R Core Team, 2017).
Ethical approval
The study of hepatitis E among PERSIMUNE patients was
approved by the Regional Scientific Committee for the Capital
Region of Denmark (H-16040755). The donor investigation was
approved as a quality control project (H-2–2014FSP42).
Results
PERSIMUNE patients
Among the 4062 adult patients (18 years old) enrolled within
the first 2-year period of the PERSIMUNE cohort in Denmark, five
patients had withdrawn their consent, 32 had a replacement social
security number that was not compatible with access to treatment
databases, and two patients lacked enough sample material. Thus,
a total of 4023 patients were included in the study. Patient
characteristics are summarized in Table 1. A total of 843 (21%)Table 1
Baseline characteristics of all patients; total N = 4023 (100%).
At time of Biobank inclusion of patients tested for HEV
markers
Number of patients
(%)
Sex
Male 2793 (69.4)
Female 1230 (30.6)
Age, median (IQR) years 54 (42–67)
Age divided in age groups, years
<30 351 (8.7)
30–39 528 (13.1)
40–49 802 (19.9)
50–59 801 (19.9)
60–69 889 (22.1)
70 652 (16.2)
HIV diagnosis 1162 (28.9)
Non-HIV diagnosis 2861 (71.1)
TX treatment (SOT or allo-HSCT) 843 (21.0)
Non-TX treatment 3180 (79.0)
Affiliation of patients with departments at Rigshospitalet
Department of Infectious Diseasesa 1469 (36.9)
HIV 1154 (28.7)
Non-HIV 315 (7.9)
Department of Haematologyb 855 (21.3)
Allo-HSCT 344 (8.6)
Non-HSCT 511 (12.7)
Department of Oncologyc 825 (20.5)
Department of Nephrologyd 679 (16.9)
SOT 437 (10.9)
Non-SOT 242 (6.0)
Department of Hepatology or Liver Surgerye 100 (2.5)
SOT 27 (0.7)
Non-SOT 73 (1.8)
Department of Rheumatologyf 50 (1.2)
Department of Cardiology or Thoraco-surgeryg 45 (1.1)
SOT 35 (0.9)
Non-SOT 10 (0.2)
HEV, hepatitis E virus; IQR, interquartile range; TX, transplantation; SOT, solid organ
transplant patients; allo-HSCT, allogeneic haematopoietic stem cell transplant
patients. Inclusion criteria, diagnosis of patients: aHIV infection, common variable
immunodeficiency, cystic fibrosis. bMalignant haematological disease, leukaemia,
myelomatosis or lymphoma and allo-HSCT. cPatients before or on chemotherapeu-
tic treatment, for solid organ malignancy: cancer in the lungs, pleura, bladder,
prostate, testicles, head and throat. dKidney transplantation, haemodialysis or
peritoneal dialysis, vasculitis with kidney morbidity. eAutoimmune hepatitis, liver
transplantation. fRheumatological conditions treated with immunomodulating
drugs. gHeart and lung transplantation, before heart surgery.patients were treated with TX, of whom 344 were treated with
allo-HSCT. Patients treated with SOT (n = 499) included 437 kidney,
27 liver, 22 heart, and 13 lung transplantation patients.
Among the 4023 patients, six were initially HEV RNA reactive
and were confirmed to be HEV RNA reactive. Of these six patients,
two had been treated with allogeneic HSCT and one patient had
received a kidney transplantation (Table 2). The HEV RNA
prevalence overall was 0.15% (95% CI 0.07–0.33%) and was 0.36%
(95% CI 0.12–1.06%) among the TX subgroup; when broken down
by allo-HSCT and SOT recipients, the prevalence was 0.58% (95% CI
0.16–2.1%) and 0.21% (95% CI 0.04–1.2%), respectively.
The HEV RNA prevalence rate of 0.15% (95% CI 0.07–0.33%) was
slightly higher in this Danish PERSIMUNE cohort compared with an
HEV RNA prevalence rate of 0.04% (95% CI 0.02–0.07%) determined
among Danish blood donors (p = 0.009) using the same
methodology (Harritshoj et al., 2016).
Among the five patients alive for follow-up, clearance of HEV
viraemia and anti-HEV seroconversion were detected in the first
follow-up sample at 12–26 months after enrolment. Persistent
HEV infection during the first year after enrolment was not
assessable due to the lack of sample material. Patient 5 had cleared
the HEV infection in the first follow-up sample at 21 months after
enrolment, but tested anti-HEV IgG-negative in the Wantai assay.
However, anti-HEV IgG was detectable using another assay,
recomWell (Mikrogen Diagnostik, Neuried, Germany). One patient
died (breast cancer) before the possibility of follow-up.
The immunological status at enrolment of the HEV viraemic
patients (patients 1–5) included lymphocyte counts ranging
between 0.7  109/l and 2.9  109/l and neutrophil counts
ranging between 4.5  109/l and 8.1 109/l. In one 85-year-old
patient with atypical chronic myeloid leukaemia, higher values
included a lymphocyte count of 6.1  109/l and a neutrophil
count of 20.7  109/l.
No symptoms of hepatitis or neurological disorders were
described in five of the six patients available for follow-up. The
patient notes revealed gastrointestinal symptoms including
diarrhoea and/or abdominal pain in three patients. Two patients
showed ALT elevation at the time of HEV diagnosis.
A 54-year-old female (patient 2) treated with sirolimus after
allo-HSCT 45 months prior to the HEV diagnosis, had a high HEV
viraemia level (590 059 IU/ml) and a peak ALT of 1100 IU/ml by the
enrolment date. The normal ALT value of 27 IU/ml at 1 month
before and the decline in value reaching 35 IU/ml at 5 weeks after
enrolment were consistent with undiagnosed acute resolving
hepatitis, with stomach ache as the only subjective symptom.
A minor ALT elevation (70 IU/ml) was found in a 47-year-old
woman (patient 5) with anaemia and a diagnosis of coeliac disease,
which had caused a continuous minor ALT elevation for years; this
was also measured at follow-up after HEV RNA clearance.
A high HEV viraemia level (449 332 IU/ml) was also detected in
patient 3, who was treated with the immunosuppressive drugs
tacrolimus and mycophenolate mofetil due to a kidney transplan-
tation 30 months prior to PERSIMUNE enrolment. Four months
after HEV diagnosis, a 3-week period with diarrhoea was
described. ALT values were registered at the enrolment date and
6 months after, with normal values (32 and 36 IU/ml).
A medium level of HEV viraemia (5714 IU/ml) was detected in a
41-year-old male (patient 4) no longer on any immunosuppressive
drug after allo-HSCT 42 months prior to his HEV diagnosis. No
infectious symptoms were described, and normal values of ALT
were detected at 6 months before the HEV diagnosis and until 18
months after.
A total of 885 PERSIMUNE patients were anti-HEV IgG-positive
with an HEV seroprevalence of 22% (95% CI 20.7–23.3%). Of these,
20 patients (0.5%; 95% CI 0.3–0.8%) were anti-HEV IgM-positive.
The seroprevalence increased with age, whereas individuals living
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IgG-positive on univariate logistic regression analysis (Table 3).
Only age and HIV status remained statistically significant in the
multivariable logistic regression analysis, with a 65% increased risk
of anti-HEV positivity per 10 years (Table 3). The median (IQR)
CD4 + T cell counts among HIV-infected individuals did not
differ between anti-HEV IgG-positive and anti-HEV IgG-negative
patients, with 0.69 (IQR 0.36)  109 cells/l and 0.67 (IQR 0.42)  109
cells/l, respectively.
Of patients living in the Copenhagen capital region affiliated
with the Capital Region Blood Service (n = 3128 patients), 27.7% had
received blood transfusions with a median of 9 blood components
(IQR 3–15, range 1–524 blood components). A multivariable
logistic regression analysis in this subpopulation showed that the
number of blood transfusions was not positively associated with
anti-HEV positivity. Conversely, receiving more transfusions was
associated with a slightly lower anti-HEV positivity (p = 0.04)
(Supplementary Material, Table S1). Additionally, a non-significant
result was obtained (p = 0.46) when restricting to a 5-year
transfusion history in order to increase the possibility that patients
had lived in the Capital Region for the entire observation period
and thereby had not received blood transfusions from other blood
services in Denmark (data not shown).
Comparison of patients and blood donors
Of 1226 blood donors from all five regions of Denmark with a
median age of 42 years (IQR 30.5–53.5 years, range 17–67 years),134
were anti-HEV IgG-positive, yielding an HEV seroprevalence of 10.9%
(95% CI 9.3–12.8%). Of these, four donors were anti-HEV IgM-positive
(0.3%; 95% CI 0.1–0.8%). Although the overall prevalence of anti-HEV
IgG among the immunocompromised patients (22%) was higher
than among blood donors in the same period of 2015–2017
(p < 0.0001), this was not significant when adjusting for age and
sex: OR 1.20 (95% CI 0.97–1.48) (p = 0.1). An anti-HEV IgG frequency
plot showed a similar increase in seroprevalence by age in both
groups (Figure 1). Similarly, in a sub-analysis comparing blood
donor anti-HEV positivity with individuals living with HIV or TX
patients, we found no significant difference in anti-HEV positivity
when adjusting for age and sex (p = 0.9 and p = 0.5, respectively);
data not shown.
HEV ORF1 and ORF2 fragments were successfully sequenced for
three patients who were all infected with HEV genotype 3 (HEV-3).
One genotype had the highest homology to the 3c subtype, and two
could not be assigned a subtype but were part of the 3efg clade
(Figure 2).
Discussion
HEV-3 infections may persist and become chronic in immuno-
deficient patients (Kamar et al., 2008). In the current cross-
sectional study of 4023 immunocompromised patients, we did not
find this to be the case for any of the six patients who were
determined to have HEV RNA viraemia.
The reported difference in HEV RNA prevalence rates in various
studies is largely related to geographical region and to some extent
to the sensitivity of the methods used. HEV RNA prevalence varies
greatly among blood donor populations in European countries
(Domanovic et al., 2017; Boland et al., 2019). The HEV RNA
prevalence rate was slightly higher in our Danish PERSIMUNE
cohort compared with the HEV RNA prevalence rate of 0.04% found
among Danish blood donors (Harritshoj et al., 2016). In the
Netherlands and the UK, HEV RNA-positive fractions among
patients with allo-HSCT or haematological malignancies were 2.4%
and 0.13%, respectively (Versluis et al., 2013; Ankcorn et al., 2019).
Additionally, 1% and 1.16% HEV RNA reactivity were detected
Table 3
Risk factors for anti-HEV IgG seropositivity based on all patients tested.
Variable Univariable logistic regression analysis Multivariable logistic regression analysis
Anti-HEV IgG positivity n/N (%) OR (95% CI) p-Value OR (95% CI) p-Value
Total n/N 885/4023 (22.0) Anti-HEV IgG
positivity
Anti-HEV IgG
positivity
Sex 1.01 (0.86–1.19) 0.90 1.15 (0.96–1.38) 0.13
Male 616/2793 (22.1)
Female 269/1230 (21.9)
Effect of age, per 10 yearsa 1.67 (1.58–1.77) <0.001 1.65 (1.55–1.75) <0.001
Age (years)
<30 15/351 (4.3)
30–39 57/528 (10.8)
40–49 100/802 (12.5)
50–59 149/801 (18.6)
60–69 289/889 (32.5)
70 275/652 (42.2)
HIV diagnosis 183/1162 (15.7) 0.57 (0.48–0.69) <0.001 0.59 (0.42–0.85) 0.003
Non-HIV 702/2861 (24.5)
TX treatment (SOT or allo-HSCT) 154/843 (18.3) 0.75 (0.62–0.91) 0.003 0.84 (0.65–1.08) 0.17
Non-TX treatment 731/3180 (23.0)
Affiliation with department
Department of Infectious Disease 235/1469 (16.0) 1.24 (0.56–3.28) Inf vs. Car 0.63 1.84 (0.75–5.24) 0.21
Department of Haematology 220/855 (25.7) 2.25 (1.01–5.99) Hae vs. Car 0.07 1.43 (0.61–3.91) 0.44
Department of Oncology 239/825 (28.0) 2.65 (1.19–7.04) Onc vs. Car 0.03 1.48 (0.63–4.10) 0.40
Department of Nephrology 157/679 (23.1) 1.95 (0.87–5.22) Nep vs. Car 0.13 1.70 (0.73–4.67) 0.25
Department of Hepatology or Liver Surgery 15/100 (15.0) 1.15 (0.43–3.42) Hep vs. Car 0.79 1.34 (0.48–4.15) 0.59
Department of Rheumatology 13/50 (26.0) 2.28 (0.81–7.08) Rhe vs. Car 0.13 2.28 (0.76–7.49) 0.15
Department of Cardiology or Thoraco-surgery 6/45 (13.3) 1 1
Anti-HEV IgG, antibodies against hepatitis E virus immunoglobulin G; OR, odds ratio; CI, confidence interval; SOT, solid organ transplantation; allo-HSCT, allogeneic
haematopoietic stem cell transplantation; TX, transplantation; Inf, Department of Infectious Disease; Car, Department of Cardiology or Thoraco-surgery; Hae, Department of
Haematology; Onc, Department of Oncology; Nep, Department of Nephrology; Hep, Department of Hepatology or Liver surgery; Rhe, Department of Rheumatology.
a Linear variable.
Figure 1. Anti-HEV frequency by age.
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compared with 0.13% and 0.04% HEV RNA reactivity among blood
donors (Hogema et al., 2016; Hewitt et al., 2014).
However, a higher fraction of HEV RNA positivity among
immunocompromised patients compared with blood donors may
indicate longer periods of HEV viraemia among immunocompro-
mised patients due to less effective clearance of the infection.
The courses of the HEV infections in this study were either acute
and self-limiting or subclinical. Among three HEV RNA viraemic TX
patients, two were treated with immunosuppressive drugs. In
general, the HEV RNA viraemic patients in this study were not
profoundly immunosuppressed according to their lymphocyte cell
counts at the time of HEV diagnosis, reducing the risk of
developing chronic HEV infections. Among SOT patients, the
calcineurin inhibitor tacrolimus, which blocks T cell activation, hasbeen shown to be an independent risk factor associated with
chronic HEV infections (Kamar et al., 2011). Additionally, chronic
HEV infections among SOT patients are more likely to develop in
profoundly immunosuppressed patients. In particular, the CD2,
CD3, and CD4 T cell subpopulations are significantly lower in
patients with chronic HEV infections than in those who clear the
infection spontaneously (Kamar et al., 2008). Data on T cell
subpopulations were not available in this patient group. The HEV
RNA viraemic patient in this study who received tacrolimus for
prophylaxis of organ rejection had a total lymphocyte cell count
below the normal range. However, this patient cleared the HEV
infection spontaneously, indicating that the T cell count in this
patient was not heavily suppressed.
The principal transmission route for HEV-3 is supposedly food-
borne, mainly from pig products that are insufficiently cooked,
although environmental transmission routes from irrigation water
or living in close contact with animals are also known risk factors
common to both healthy and immunologically vulnerable persons
(Van der Poel, 2014). Transfusion transmitted HEV infections (TTI)
have been described in case reports and larger observational
studies (Hewitt et al., 2014), and TTI in multi-transfused patients
may also explain a higher HEV RNA prevalence among immuno-
compromised patients, who often receive multiple transfusions
during the course of a transplant process. However, in this study,
TTI as the cause of active HEV infection was refuted by look-back
procedures.
In the assessment of factors associated with anti-HEV positivity,
old age and non-HIV status were significantly associated with anti-
HEV positivity, whereas individuals living with HIV were not. The
lower odds of anti-HEV positivity among HIV-infected individuals
compared with immunocompromised patients without HIV and
the similar odds of anti-HEV positivity compared with age- and
sex-matched blood donors are in concordance with other studies
of HIV-infected individuals and co-infection with HEV. A case–
control study performed in southern France showed that
Figure 2. Phylogenetic tree of hepatitis E virus genotype 3 (HEV-gt3), including genotypes gt1 and gt2. Sequences of ORF2 from a 1390-bp fragment or smaller. Reference
sequences (normal type) and sequences from Danish gt3 (bold type with year of diagnosis). gt3 from immunocompromised Danish patients (large font: Dk, 2019, pat 2–4),
Danish blood donors (2016 Dk_Donor4–5), previously diagnosed symptomatic Danish patients (Dk, year), and from Danish pig livers (Dk, year, pig).
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than age- and sex-matched blood donors living in the same area
(38.7%) (Abravanel et al., 2017). Correspondingly, Keane et al. found
no difference between HIV-infected persons (9.4%) and age- and
sex-matched non-HIV-infected patients (13.8%) living in England.
The HIV-infected population in our study is supposedly
well treated with combination antiretroviral therapy (c-ART) —
in accordance with the general treatment for HIV across Denmark.
We found no difference in CD4 + T cell count betweenanti-HEV-positive and anti-HEV-negative individuals. In accor-
dance with these results, HIV-infected patients in Argentina with a
normal CD4 + T cell count had an HEV seroprevalence similar to
that of a non-HIV-infected immunocompetent population (Debes
et al., 2016). The results indicate that persons living with HIV in
Denmark do not have a higher risk of an HEV infection.
Additionally, neither transplantation history nor blood trans-
fusion history was associated with anti-HEV positivity. The latter is
in contrast to a recent study among patients with a diagnosis of
194 L.H. Harritshøj et al. / International Journal of Infectious Diseases 91 (2020) 188–195haematological malignancy, showing a linear increase in anti-HEV
IgG seropositivity with the number of transfusions received during
a 5-year period, suggesting HEV acquisition via blood transfusion
(Ankcorn et al., 2019). These deviating results may be due to
differences in unknown fractions of transfusion history outside the
local hospital/region. However, we did not find any evidence of a
correlation between the number of transfusions received and HEV
seropositivity when restricting transfusion history to a 5-year
period, as also reported by the authors of the UK study. Estimates of
TTI HEV risk have suggested that exposure to 13 blood components
from blood donors living in the same geographical area equals the
background exposure of 1 year of daily living in the same area
(Tedder et al., 2017).
We found a 65% increased risk of anti-HEV positivity per 10
years of increasing age. The anti-HEV frequencies of donors and
patients in relation to age were similar, and the difference in
seroprevalence was mainly explained by age, as described in earlier
studies (Holm et al., 2015). When comparing different populations
in cross-sectional anti-HEV seroprevalence studies, the median age
and IQR of the populations investigated, or alternatively age-
weighted seroprevalence, should be included in the judgement as
well.
This study has strengths and limitations. This was a large
cross-sectional study of immunocompromised patients investi-
gated for HEV epidemiology and the first large HEV RNA
investigation in Denmark among this patient category. Addi-
tionally, the ability to compare results with blood donor studies
from the same country and during the same time period using
identical testing methods provides a sound basis for investigat-
ing both common and differential transmission risks of HEV
infection.
Limitations of the study include the absence of follow-up
samples within the first year of follow-up, excluding any
possible detection of HEV RNA persistence in HEV RNA-positive
patients. Another limitation is that this investigation is a point
cross-sectional study, in which the sampling time was random
in relation to the course of the diagnosis causing the
immunodeficiency. This may have resulted in an underestima-
tion of the prevalence rates of HEV RNA and the number of
detected chronic HEV infections. However, a recent study among
HSCT (allogeneic and autologous) and SOT patients in the peri-
transplant period in the UK did not detect higher prevalence
rates (0.46%) or more chronic HEV infections compared with a
randomly sampled study among allo-HSCT and SOT transplant
patients from the UK as well (0.67%) (Reekie et al., 2018;
Ankcorn et al., 2018).
In conclusion, the HEV RNA prevalence was 0.15% in a Danish
cohort of immunocompromised patients. There were higher rates
of 0.58% and 0.21% in the allogeneic HSCT and SOT patient
subgroups, respectively. All HEV viraemic patients anti-HEV
seroconverted spontaneously, and no evidence of symptomatic
chronic HEV infections was found. Transfusion history was not
associated with active or former HEV infections in this study. A
high HEV seroprevalence rate of 22% in the PERSIMUNE cohort did
not differ from the seroprevalence in Danish blood donors (10.9%)
when adjusting for age and sex. The results support the food-
borne/environmental transmission of HEV as the main transmis-
sion route common to both vulnerable immunocompromised
patients and healthy blood donors. However, the possibility of HEV
infection should be considered in TX patients with liver enzyme
elevations.
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